Mangalam Drugs & Organics Ltdte (BSE: 532637) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹49 Cr, it ranks #3,878 by market cap among the 6,137 Indian listed companies on FinBizNet, and #76 of 86 in Medicinal Chemicals and Botanical Products. At ₹28.65 (as of 25 Oct 2026), the share price is 59.6% below its 52-week high of ₹70.86 and 25.7% above its 52-week low of ₹22.80. The share price is down 58.6% over one year and up 5.3% over three months.
| Current Price | ₹28.65 |
|---|---|
| Market Cap | ₹49 Cr |
| BSE Code | 532637 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | -1.1 |
| Return on Equity | -35.23% |
| Return on Assets | -5.96% |
| 52-Week Range | ₹22.80 – ₹70.86 |
| 1-Year Price Change | -58.6% |
| 3-Month Price Change | +5.3% |
| Beta (1Y) | 0.35 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.mangalamdrugs.com |
| Revenue | ₹57 Cr |
|---|---|
| Net Profit | ₹-8 Cr |
| Net Margin | -13.4% |
| EPS (Basic) | ₹-4.83 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers active pharmaceutical ingredients (API) products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, etodolac, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, olanzapine, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate. It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base; and tenofovir disoproxil base. In addition, the company offers specialty chemicals comp
1. Manufacturing of Bulk Drugs-This segment manufactures and sells drugs, medicines, and allied products. 2. Chemicals & Others-0 3. Segment Adjustment-This segment manufactures organic chemicals, prefumery/specialty chemicals, disperse dye intermediates, and dye products. 4. Corporate-0
1. Manufacturing of Bulk Drugs-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Mangalam Drugs & Organics Ltdte | ₹49 Cr | -1.1 | -35.23% | ₹57 Cr | -58.6% |
Listed by market capitalisation. Ratios are shown for context only.
Mangalam Drugs & Organics Ltdte is trading at ₹28.65, with a market capitalisation of ₹49 Cr.
Mangalam Drugs & Organics Ltdte operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Mangalam Drugs & Organics Ltdte has a P/E of -1.1 and a return on equity of -35.23%.
Mangalam Drugs & Organics Ltdte is listed on the BSE under the scrip code 532637.
Mangalam Drugs & Organics Ltdte's share price is down 58.6% over one year and up 5.3% over three months. Its 52-week range is ₹22.80 to ₹70.86.
In Q1 FY27, Mangalam Drugs & Organics Ltdte reported revenue of ₹57 Cr and net profit of ₹-8 Cr, with basic EPS of ₹-4.83 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.